JP2019532031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532031A5 JP2019532031A5 JP2019511658A JP2019511658A JP2019532031A5 JP 2019532031 A5 JP2019532031 A5 JP 2019532031A5 JP 2019511658 A JP2019511658 A JP 2019511658A JP 2019511658 A JP2019511658 A JP 2019511658A JP 2019532031 A5 JP2019532031 A5 JP 2019532031A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylenyl
- hydrogen
- heterocyclyl
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000004452 carbocyclyl group Chemical group 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 125000005466 alkylenyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- VZKYFJQZMLDYED-UHFFFAOYSA-N CC(C)NC(CN1CCCC1)=O Chemical compound CC(C)NC(CN1CCCC1)=O VZKYFJQZMLDYED-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381383P | 2016-08-30 | 2016-08-30 | |
| US62/381,383 | 2016-08-30 | ||
| US201662437533P | 2016-12-21 | 2016-12-21 | |
| US62/437,533 | 2016-12-21 | ||
| PCT/US2017/049462 WO2018045084A1 (en) | 2016-08-30 | 2017-08-30 | Tetracycline compounds and methods of treatment |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019532031A JP2019532031A (ja) | 2019-11-07 |
| JP2019532031A5 true JP2019532031A5 (https=) | 2020-10-08 |
| JP7184756B2 JP7184756B2 (ja) | 2022-12-06 |
| JP7184756B6 JP7184756B6 (ja) | 2022-12-20 |
Family
ID=59982459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511658A Active JP7184756B6 (ja) | 2016-08-30 | 2017-08-30 | テトラサイクリン化合物および処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230031954A1 (https=) |
| EP (1) | EP3506908A1 (https=) |
| JP (1) | JP7184756B6 (https=) |
| KR (1) | KR102558540B1 (https=) |
| CN (1) | CN110167560B (https=) |
| AU (1) | AU2017319513B2 (https=) |
| CA (1) | CA3034891A1 (https=) |
| CL (1) | CL2019000542A1 (https=) |
| CO (1) | CO2019002975A2 (https=) |
| IL (1) | IL264878B (https=) |
| MA (1) | MA46102A (https=) |
| MX (1) | MX2019002453A (https=) |
| MY (1) | MY204572A (https=) |
| SG (2) | SG11201901390TA (https=) |
| WO (1) | WO2018045084A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2883238C (en) | 2012-08-31 | 2021-11-23 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| HUE066360T2 (hu) | 2016-10-19 | 2024-07-28 | Tetraphase Pharmaceuticals Inc | Eravaciklin kristályformái |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| WO2021022258A1 (en) * | 2019-08-01 | 2021-02-04 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds for the treatment of hematological cancers |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| PH12022553378A1 (en) | 2020-06-10 | 2024-03-25 | Univ Leuven Kath | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1077598A (en) * | 1965-05-12 | 1967-08-02 | Pfizer & Co C | Preparation of n-demethyl tetracyclines |
| WO2005082860A1 (en) * | 2004-02-27 | 2005-09-09 | National Research Council Of Canada | Tetracyclines and their use as calpain inhibitors |
| CN101010315A (zh) * | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| KR101746795B1 (ko) * | 2008-08-08 | 2017-06-13 | 테트라페이즈 파마슈티컬스, 인코포레이티드 | Ｃ７-플루오로 치환된 테트라시클린 화합물 |
| ES2440000T3 (es) | 2009-05-08 | 2014-01-27 | Tetraphase Pharmaceuticals, Inc. | Compuestos de 8-aza-tetraciclina |
| WO2010129057A2 (en) | 2009-05-08 | 2010-11-11 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| NO2470500T3 (https=) * | 2009-08-28 | 2018-03-03 | ||
| WO2011109899A1 (en) * | 2010-03-10 | 2011-09-15 | University Health Network | Use of tigecycline for treatment of cancer |
| DK2552890T3 (en) * | 2010-03-31 | 2017-04-03 | Tetraphase Pharmaceuticals Inc | POLYCYCLIC TETRACYCLINE COMPOUNDS |
| KR101770979B1 (ko) | 2010-05-21 | 2017-08-24 | 애브비 인코포레이티드 | 5ｈｔ 수용체의 조절제 및 이의 사용방법 |
| AR082633A1 (es) * | 2010-08-12 | 2012-12-19 | Tetraphase Pharmaceuticals Inc | Analogos de tetraciclina |
| SE536617C2 (sv) | 2012-06-28 | 2014-04-01 | Cargine Engineering Ab | Metod och positioneringssensorsammansättning för fastställning av en inbördes position mellan ett första objekt och ettandra objekt |
| CA2883238C (en) * | 2012-08-31 | 2021-11-23 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
-
2017
- 2017-08-30 IL IL264878A patent/IL264878B/en unknown
- 2017-08-30 EP EP17777422.1A patent/EP3506908A1/en active Pending
- 2017-08-30 CN CN201780064847.8A patent/CN110167560B/zh active Active
- 2017-08-30 CA CA3034891A patent/CA3034891A1/en active Pending
- 2017-08-30 SG SG11201901390TA patent/SG11201901390TA/en unknown
- 2017-08-30 WO PCT/US2017/049462 patent/WO2018045084A1/en not_active Ceased
- 2017-08-30 MY MYPI2019001102A patent/MY204572A/en unknown
- 2017-08-30 MX MX2019002453A patent/MX2019002453A/es unknown
- 2017-08-30 MA MA046102A patent/MA46102A/fr unknown
- 2017-08-30 KR KR1020197008575A patent/KR102558540B1/ko active Active
- 2017-08-30 US US16/328,559 patent/US20230031954A1/en not_active Abandoned
- 2017-08-30 JP JP2019511658A patent/JP7184756B6/ja active Active
- 2017-08-30 AU AU2017319513A patent/AU2017319513B2/en not_active Ceased
- 2017-08-30 SG SG10202101986UA patent/SG10202101986UA/en unknown
-
2019
- 2019-02-28 CL CL2019000542A patent/CL2019000542A1/es unknown
- 2019-03-27 CO CONC2019/0002975A patent/CO2019002975A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532031A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| JP2015501833A5 (https=) | ||
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) | |
| JP2014511892A5 (https=) | ||
| JP2015514806A5 (https=) | ||
| CA2412968A1 (en) | Substituted pyridines as selective cyclooxygenase-2 inhibitors | |
| GB201201744D0 (en) | Novel compounds | |
| JP2017537949A5 (https=) | ||
| JP2018535963A5 (https=) | ||
| JP2016530259A5 (https=) | ||
| JP2014505660A5 (https=) | ||
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| JP2018516917A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2014511891A5 (https=) | ||
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| JP2020500182A5 (https=) | ||
| JP2021518400A5 (https=) | ||
| JP2018534288A5 (https=) | ||
| JP2021501756A5 (https=) | ||
| JP2019504067A5 (https=) | ||
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена | |
| RU2016115487A (ru) | Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda |